The ARHGEF1 Knockout HEK293T Polyclonal Cells consist of a genetically heterogeneous population of HEK293T cells engineered via CRISPR/Cas9-mediated disruption of the ARHGEF1 gene. This polyclonal knockout cell pool provides a versatile loss-of-function model for interrogating ARHGEF1-dependent signaling and cellular processes without the selection biases associated with clonal lines. The knockout product format enables researchers to assess the collective impact of ARHGEF1 deficiency across a diverse spectrum of editing outcomes, making it particularly useful for robust functional genomics studies and high-throughput screening applications.
HEK293T cells are an extensively characterized human embryonic kidney epithelial cell line stably expressing the SV40 large T-antigen. Known for their high transfection efficiency and robust protein expression capacity, HEK293T cells have become a workhorse in molecular and cellular biology, routinely employed for ectopic protein production, lentiviral packaging, and detailed mechanistic dissection of signaling cascades. Their adherent growth and well-defined epithelial morphology facilitate reproducible imaging-based assays and biochemical analyses, rendering them an ideal host for studies of cytoskeletal dynamics, cell adhesion, and receptor-mediated signaling.
ARHGEF1 encodes a guanine nucleotide exchange factor that activates the small GTPase RhoA. It is activated by G??12/13-coupled receptors and integrin clustering, linking external stimuli to actin reorganization. ARHGEF1 catalyzes GDP/GTP exchange on RhoA, engaging Rho-associated coiled-coil kinase (ROCK) and LIM domain kinase (LIMK). Downstream, phosphorylation of myosin light chain (MLC) and cofilin drives stress fiber formation and focal adhesion assembly. ARHGEF1 also interacts with focal adhesion kinase (FAK) and paxillin, integrating signals from receptor tyrosine kinases such as EGFR.
In the HEK293T background, ARHGEF1 knockout selectively ablates a central node in RhoA activation, allowing precise dissection of its contribution to GPCR- and integrin-mediated pathways that are otherwise masked by compensatory mechanisms. Given the cell line??s widespread use in signaling research, this model is especially relevant for uncovering ARHGEF1??s role in pathological processes like cancer cell migration, invasion, and metastasis, as well as in cardiovascular pathologies including hypertension and cardiac hypertrophy. The polyclonal population diminishes clonal artifacts and provides a more physiologically representative range of knockout efficiencies, improving the generalizability of experimental findings.
This polyclonal knockout cell product is suited for a broad array of assays, including RhoA activation assays (Rhotekin pull-down), immunofluorescence visualization of actin stress fibers and focal adhesions, transwell migration and invasion assays, and adhesion assays. It also supports co-immunoprecipitation studies to probe ARHGEF1 interactions with G??12/13 or FAK, and phospho-MLC immunoblotting. By enabling the study of ARHGEF1-regulated cytoskeletal dynamics and adhesion signaling, this model serves as a valuable tool for drug target validation in metastatic disease and mechanotransduction research. For further technical information or assistance with custom gene editing projects, please contact Ascent Research.
